Abby Hardy, Author at BioTuesdays

Markets

SVB Leerink starts Organogenesis at OP; PT $9

SVC Leerink initiated coverage of Organogenesis (NASDAQ:ORGO) with an “outperform” rating and $9 price target. The stock closed at $4.84 on Jan. 9. Organogenesis is a regenerative medicine company with a portfolio of...

January 10, 2020

Markets

Canaccord ups Profound Medical PT to $20 from $14

Canaccord Genuity raised its price target for Profound Medical (NASDAQ:PROF; TSX:PRN) to $20 from $14 after the company announced preliminary Q4-2019 results. Shares of Profound were quoted at $14.72, up $1.73, or 13%...

January 10, 2020

Markets

Maxim ups Cassava Sciences PT to $12 from $3

Maxim Group raised its price target for Cassava Sciences (NASDAQ:SAVA) to $12 from $3, citing the recent rise in the company’s share price. The stock closed at $7.93 on Jan. 9. “Cassava’s shares have risen significantly...

January 10, 2020

Developments

Profound Medical inks its first U.S. multicenter agreement for TULSA-PRO; provides commercialization update

Profound Medical (NASDAQ:PROF; TSX:PRN) signed its first U.S. multi-site imaging center agreement for TULSA-PRO with RadNet (NASDAQ:RDNT), a leading provider of fixed-site outpatient diagnostic imaging services with a...

January 10, 2020

Developments

IntelGenx enters animal health market with VetaFilm feasibility agreement

IntelGenx (TSXV:IGX; OTCQX:IGXT) entered into a feasibility study agreement with an undisclosed partner focused on bringing innovative animal health products to the market. IntelGenx will conduct a feasibility study on...

January 9, 2020

Developments

Hepion to present update on CRV431 nonclinical studies at NASH-TAG 2020 conference

Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present a poster at the upcoming NASH-TAG 2020 conference. The presentation will provide details of four nonclinical studies demonstrating that CRV431 decreases liver...

January 8, 2020

Executive Moves

ArcherDX names Mark Massaro as CFO

Mark Massaro Closely-held ArcherDX appointed research industry veteran, Mark Massaro, as its CFO. “Mark’s extensive knowledge of the diagnostics landscape, coupled with his more than 20 years of industry...

January 8, 2020

Developments

Apellis reports positive topline Phase 3 data in paroxysmal nocturnal hemoglobinuria

Apellis Pharmaceuticals (NASDAQ:APLS) reported positive topline results from its Phase 3 study evaluating pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Pegcetacoplan met the study’s...

January 7, 2020

Developments

Hepion paper published in Expert Opinion on Investigational Drugs

Hepion Pharmaceuticals’ (NASDAQ:HEPA) comprehensive review of studies on the role of cyclophilins in non-alcoholic steatohepatitis (NASH) and NASH-related liver disease has been published in peer-reviewed journal...

January 6, 2020

Developments

X4 Pharma starts Phase 1b trial of mavorixafor for Waldenström’s macroglobulinemia

X4 Pharmaceuticals (NASDAQ:XFOR) initiated a Phase 1b trial of mavorixafor in combination with ibrutinib, a Burton tyrosine kinase (BTK) inhibitor, for the treatment of Waldenström’s macroglobulinemia (WM). WM is a rare...

December 30, 2019

Author - Abby Hardy

SVB Leerink starts Organogenesis at OP; PT $9

Canaccord ups Profound Medical PT to $20 from $14

Maxim ups Cassava Sciences PT to $12 from $3

Profound Medical inks its first U.S. multicenter agreement for TULSA-PRO; provides commercialization update

IntelGenx enters animal health market with VetaFilm feasibility agreement

Hepion to present update on CRV431 nonclinical studies at NASH-TAG 2020 conference

ArcherDX names Mark Massaro as CFO

Apellis reports positive topline Phase 3 data in paroxysmal nocturnal hemoglobinuria

Hepion paper published in Expert Opinion on Investigational Drugs

X4 Pharma starts Phase 1b trial of mavorixafor for Waldenström’s macroglobulinemia

Subscribe